"Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy." by Celestia S. Higano

Article

Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.

Journal of Clinical Oncology (2020)

Celestia S. Higano, Fred Hutchinson Cancer Research Center
Lauren C Harshman, Harvard University
Sabina Dizdarevic, Brighton and Sussex Medical School
John Logue, Oncology Department-Uro-Oncology team, The Christie NHS Foundation Trust, Manchester, United Kingdom;
Timothy Richardson, Urology, GU Research Network-Wichita Urology Group, Wichita, KS;
Saby George, Roswell Park Cancer Institute
Danny Song, Johns Hopkins University
Igle J. de Jong, University Medical Center Groningen
Jeffrey Tomaszewski, Cooper University Hospital
Fred Saad, Université de Montréal
Kurt Miller, Charité
Jeffrey Meltzer, Bayer HealthCare Pharmaceuticals
Per Sandstrom, Bayer HealthCare Pharmaceuticals
Bertrand F. Tombal, Division of Urology, IREC, University Hospital Saint Luc, Brussels, Belgium;
A. Oliver Sartor, Tulane University

Link

Disciplines

Publication Date

May 20, 2020

DOI

10.1200/JCO.2020.38.15_SUPPL.5542

Citation Information

Celestia S. Higano, Lauren C Harshman, Sabina Dizdarevic, John Logue, et al.. "Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy." Journal of Clinical Oncology Vol. 38 Iss. 15 (2020) p. 5542 - 5542
Available at: http://works.bepress.com/jeffrey-tomaszewski/114/